Assessing potentials of plasma amyloid beta 42 and tau levels for alzheimer's disease diagnosis by testing immunomagnetic reduction technology in a sun city cohort

Lih-Fen Lue,Marwan N. Sabbagh,Andre Guerra,Douglas Gordon Walker,Kewei Chen,Eric M. Reiman

DOI: https://doi.org/10.1016/j.jalz.2017.07.635

2017-01-01

Alzheimer s & Dementia

Abstract:Research assessing potentials of Alzheimer's disease core pathological markers, amyloid beta 42 and tau, in plasma as diagnostic biomarkers have yielded inconsistent findings. One of the challenges has been the limitation of detection sensitivity and specificity of the assays used to measure these markers that are present at low picogram per milli-liter concentration in protein-rich samples. Immunomagnetic reduction (IMR) assays are among a few new technologies demonstrating super-sensitivity in detecting these proteins. However, these assays had not been used previously to measure clinical samples collected from any cohort residing outside Taiwan, where the technology was developed. Therefore, we conducted the first pilot study to assess the ability of IMR-assayed plasma total tau and amyloid beta 42 in distinguishing patients with the clinical diagnosis of late-onset Alzheimer's dementia from cognitively normal older adults. The participants were recruited at the clinic of Banner Sun Health Research Institute in Sun City of Arizona. Plasma samples were obtained from 32 subjects, 82 ± 1 years of age, including 16 patients with the clinical diagnosis of moderate Alzheimer's dementia (AD) and 16 normal control (NCs). For our main comparison, ultra-sensitive IMR-based assays were used to measure plasma tau and amyloid beta 42 levels. All assays were performed blind to subject classification or demographic features. The objective of the statistical analysis was to determine sensitivity, specificity, cut-off values, and area under curve for identifying Alzheimer's dementia in this cohort. The patient group had significantly higher plasma tau levels (P = 0.001) and a trend for higher plasma amyloid beta 42 levels (P = 0.06) than NCs. In exploratory analyses, the product of plasma tau and amyloid beta 42 levels distinguished patients from controls with 94% sensitivity and 81% specificity at cut-off value of > 362.21 (pg/ml)2. Ultra-sensitive IMR platform offers promise in the development of amyloid beta 42 and tau as blood-based biomarkers of AD. Additional studies are needed to their value in the differential diagnosis, early detection, and tracking of AD.